Anivive Awarded FDA Grant for Canine Cancer Research

Anivive Awarded FDA Grant for Canine Cancer Research

The U.S. Food and Drug Administration (FDA) has awarded Anivive, a pet health tech company, a $500,000 USD grant to continue research on  LAVERDIA™ -CA1 (verdinexor) and its effect on treating canine cancer. As one of four companies selected for the MUMS grant,...
B-Cell Lymphoma Drug Receives FDA Priority Review

B-Cell Lymphoma Drug Receives FDA Priority Review

ADC Therapeutic’s Biologics License was approved by the U.S. Food and Drug Administration (FDA) for their relapsed/refractory diffuse large B-cell Lymphoma drug candidate. The antibody conjugate drug, that catalyzes cancer cell death is being investigated in a...